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Rheumatoid arthritis (RA) is the most common systemic autoimmune disease, affecting ∼1% of the adult population
worldwide, with an estimated heritability of 60%. To identify genes involved in RA susceptibility, we investigated
the association between putative functional single-nucleotide polymorphisms (SNPs) and RA among white indi-
viduals by use of a case-control study design; a second sample was tested for replication. Here we report the
association of RA susceptibility with the minor allele of a missense SNP in PTPN22 (discovery-study allelic Pp
; replication-study allelic ), which encodes a hematopoietic-speciﬁc protein tyrosinephos-54 586.6 # 10 Pp 5.6 # 10
phatase also known as “Lyp.” We show that the risk allele, which is present in ∼17% of white individuals from
the general population and in ∼28% of white individuals with RA, disrupts the P1 proline-richmotif that is important
for interaction with Csk, potentially altering these proteins’ normal function as negative regulators of T-cell acti-
vation. The minor allele of this SNP recently was implicated in type 1 diabetes, suggesting that the variant phos-
phatase may increase overall reactivity of the immune system and may heighten an individual carrier’s risk for
autoimmune disease.
Rheumatoid arthritis (RA [MIM 180300]) is character-
ized by immune cell–mediated destruction of the joint
architecture and is two to three times more common in
women than in men (Firestein 2003). A strong genetic
component is indicated (Seldin et al. 1999; MacGregor
et al. 2000), and genome scans have identiﬁed multiple
regions linked to disease (Cornelis et al. 1998; Shiozawa
et al. 1998; Jawaheer et al. 2001, 2003; MacKay et al.
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2002; Fisher et al. 2003). Although interesting associ-
ations have been reported (Suzuki et al. 2003; Tokuhiro
et al. 2003), only alleles at the HLA-DRB1 locus have
consistently demonstrated both linkage and association
(Seldin et al 1999).
To identify genes involved in genetic predisposition to
RA, we performed a case-control association study
(called “discovery study”) with assays for 87 putative
functional SNPs (Botstein and Risch 2003) in RA can-
didate genes and/or linkage regions. The discovery study,
consisting of 475 individuals with RA and 475 individ-
ually matched controls, was obtained by Genomics Col-
laborative, Inc. (GCI). Case samples were collected from
throughout the United States, and they met the 1987
American College of Rheumatology (ACR) diagnostic
criteria for RA. All case samples were from white in-
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Table 1
Frequency of PTPN22 Genotypes in Individuals with RA and
Matched Controls in Two Independent Sample Sets
GENOTYPE
FREQUENCY OF (NO. OF INDIVIDUALS WITH)
PTPN22 GENOTYPE IN











TT .006 (3) .013 (6) .010 (9) .021 (10) .025 (21)
TC .164 (78) .251 (119) .154 (143) .273 (126) .287 (241)
CC .830 (394) .737 (350) .836 (774) .706 (327) .688 (578)
NOTE.—Genotypes were generated by use of kinetic, allele-speciﬁc PCR
(Germer et al. 2000): 0.3 ng of DNA in a 15-ml reaction containing the allele-
speciﬁc primers 5′-CCTCCACTTCCTGTAT/C and a common primer, 5′-CCCA-
TCCCACACTTTATTTTATAC. Genotyping accuracy was 100%, as deter-
mined by internal comparisons by use of a different assay (Iannone et al. 2000)
for the same marker on ∼6% of the samples. All case and control populations
were in Hardy-Weinberg equilibrium.
a Independent cases comprising one randomly selected sib per NARAC family.
b All affected individuals in NARAC.
Table 2









Crude Analysisa CLRb CLR, Adjusted for HLAc
ORd 95% CI P ORd 95% CI P ORd 95% CI P
Discovery:
TT 6 3 2.25 .56–9.07 .32e 2.26 .56–9.14 .25 2.39 .35–16.43 .38
TC 119 78 1.72 1.25–2.36 .001 1.69 1.23–2.32 .001 1.53 1.05–2.23 .03
TTTCf 125 81 1.74 1.27–2.38 .0005 1.71 1.25–2.34 .0008 1.55 1.07–2.25 .02
CC 350 394 … … … … … … … … …
Replication:
TT 10 9 2.63 1.06–6.53 .03 2.55 1.03–6.31 .04 3.26 1.03–10.28 .04
TC 126 143 2.09 1.59–2.74 !.0001 2.08 1.58–2.74 !.0001 1.7 1.19–2.42 .004
TTTCf 136 152 2.12 1.62–2.76 !.0001 2.11 1.62–2.76 !.0001 1.78 1.26–2.51 .001
CC 327 774 … … … … … … … … …
a Values were calculated by use of standard contingency tables (or two-tailed Fisher’s Exact Test).
b CLR was performed as described elsewhere (Breslow and Day 1980) to account for individual matching of controls to cases.
c To assess whether the observed associations were independent of the HLA-DRB1 genotype, we further adjusted for this known
risk factor. HLA-DRB1 genotyping was performed as described elsewhere (Jawaheer et al. 2002), and, for this analysis, samples
were binned according to their HLA-DRB1 genotype: high risk, two shared epitopes (HR-2SE); high risk, one shared epitope (HR-
1SE; 4K,X; or 4R,X); low risk, one shared epitope (LR-1SE; 1R,X; or 10,X); and low risk, zero shared epitopes (LR-0SE; X,X)
(Fries et al. 2002).
d ORs were calculated relative to the major allele homozygote (CC).
e P value calculated by use of Fisher’s Exact Test.
f Because of the infrequency of the TT genotype, we combined it with the TC genotype and repeated the analysis.
dividuals with an age at onset of RA of between 18 and
68 years and a positive rheumatoid factor of 20 IU.
Individuals with psoriasis, systemic lupus erythematosus
(SLE), ankylosing spondylitis, or Reiter syndrome were
excluded. Control samples were taken from a pool of
healthy white individuals from the United States with
no medical history of RA or of any of the autoimmune
disorders listed above. A single control was matched to
each case on the basis of sex, age (5 years), and eth-
nicity (grandparental country/region of origin). All pro-
tocols and recruitment sites have been approved by na-
tional and/or local institutional review boards, and all
subjects were enrolled with informed written consent.
We found association with the minor allele (T) of a
missense SNP (R620W [rs2476601, 1858CrT]) in the
protein tyrosine phosphatase non-receptor type 22 gene
(PTPN22) (allele frequency 13.8% in cases, 8.8% in
controls) ( , allelic odds ratio [OR] 1.65,4Pp 6.6 # 10
95% CI 1.23–2.20).
Replication in a second study (called the “replication
study”) conﬁrmed association. Cases in the replication
study were obtained by the North American Rheuma-
toid Arthritis Consortium (NARAC) and consisted of
members of white multiplex families. For this study,
DNA was available for 840 individuals with RA from
463 families. These families were recruited from
throughout the United States through the 12 partici-
pating recruitment centers of NARAC (NARAC Web
site). Informed written consent was obtained from every
subject, including all participating family members, and
the local institutional review board’s approval was se-
cured at each recruitment site. The enrollment criteria
for family participation are described in detail elsewhere
(Jawaheer et al. 2001). In brief, at least two siblingsmust
satisfy the 1987 ACR criteria for RA, at least one sibling
must have documented erosions on hand radiographs,
and at least one sibling must have disease onset between
the ages of 18 and 60 years. The presence of psoriasis,
inﬂammatory bowel disease, or SLE was an exclusionary
criterion for the sib pair. Controls were selected from
20,000 individuals who are part of theNewYorkCancer
332 Am. J. Hum. Genet. 75:330–337, 2004
Figure 1 PTPN22 knockdown by RNAi increases antigen-receptor signaling in Jurkat T-cell line. Knockdown and NF-kB transcriptional
response after T-cell receptor stimulation for cells transfected with two control siRNAs (Scramble) and two PTPN22 siRNAs. First, 4.5 mg
siRNA (Dharmacon) and 1 mg pNF-kB-luc plasmid (Stratagene) were electroporated into Jurkat cells (ATCC, clone E6-1, homozygous62# 10
for 620R) in Cell Line Nucleofector Solution V, according to manufacturer’s protocol #S18 (amaxa). After 24 h, cells were stimulated45.5# 10
with anti-CD3 (2 mg/ml [BD Pharmingen, clone UCHT1]), anti-CD28 (2 mg/ml [BD Pharmingen, clone CD28.2]), and anti-mouse IgG1 (2 mg/
ml [BD Pharmingen, clone A85-1]). Cells were lysed and assayed for luminescence 6 h after stimulation by use of Bright-Glo (Promega) and a
96-well MicroBeta plate reader (Wallac). PTPN22 siRNAs that were effective for knockdown were found by screening seven candidate siRNA
sequences that were designed by use of Web-based tools from Ambion and Dharmacon. siRNA sequences used in this study were PTPN22.1
(5′-AAGGCAGACAAAACCTATCCT), PTPN22.2 (5′-GAGGATTCCAGCTACATCAAT), Scramble.1 (5′-AAGAACGGCATCAAGGTGAAC),
and Scramble.2 (5′-AATTCTCCGAACGTGTCACGT). RNA was harvested according to the manufacturer’s protocol (RNeasy 96 [Qiagen]),
and TaqMan real-time quantitative RT-PCR (SDS-7900 [Applied Biosystems]) was used to measure PTPN22 expression levels. PTPN22 mRNA
levels in each sample were normalized to total RNA amounts (RiboGreen [Molecular Probes]) and then expressed relative to PTPN22 levels
in cells that were untransfected with siRNA. The PTPN22 TaqMan sequences were 5′-GGCCCAAAGCAAGAAAATTACTAAA (forward), 5′-
TGTCTGCCTTGTACTTGGTAGATTG (reverse), and 5′-TTCAGCTTCAGAAATT (MGB probe).
Project (NYCP), a population-based prospective study
of the genetic and environmental factors that cause dis-
ease (New York Cancer Project Web site). Two control
individuals were matched to a single randomly chosen
affected sib on the basis of sex, age (birth decade), and
ethnicity (grandparental country/region of origin). These
463 independent cases (referred to as “single sibs”) and
their 926 matched controls were used for all analyses
reported in this study, except where noted.
The association for single sibs was as follows: allele
frequency 15.8% in cases and 8.7% in controls (Pp
, allelic OR 1.97, 95% CI 1.55–2.50). An85.6 # 10
increase of the risk allele frequency was apparent when
all affected siblings ( ) were analyzed (allele fre-np 840
quency 16.8%). Genotypic analyses produced similar
results, showing increased frequencies of both TT and
TC genotypes in the cases, compared with the controls
(table 1).
We used contingency tables and conditional-logistic
regression (CLR) (Breslow and Day 1980) to assess the
association of the PTPN22 R620W genotype with RA
(table 2). In the discovery study, both the TC (ORCLR
1.69, ) and TT (ORCLR 2.26, P value not sig-Pp .0012
niﬁcant) genotypes conferred an increased risk for dis-
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Table 3











Crude Analysisa CLRb CLR, Adjusted for HLAc
ORd 95% CI P ORd 95% CI P ORd 95% CI P
Discovery:e
TTTCf RF 125 81 1.74 1.27–2.38 .0005 1.71 1.25–2.34 .0008 1.55 1.07–2.25 .02
CC RF 350 394 … … … … … … … … …
Replication:
TTTCf RF 119 122 2.38 1.78–3.18 !.0001 2.36 1.76–3.16 !.0001 2 1.35–2.97 .0005
CC RF 266 648 … … … … … … … … …
TTTCf RF 17 30 1.17 .60–2.29 .64 1.17 .60–2.31 .64 1.09 .51–2.36 .82
CC RF 61 126 … … … … … … … … …
a Values were calculated by use of standard contingency tables.
b CLR was performed as described elsewhere (Breslow and Day 1980) to account for individual matching of controls to cases.
c To assess whether the observed associations were independent of the HLA-DRB1 genotype, we further adjusted for this known risk factor.
For this analysis, samples were binned according to their HLA-DRB1 genotype: high risk, two shared epitopes (HR-2SE); high risk, one shared
epitope (HR-1SE; 4K,X; or 4R,X); low risk, one shared epitope (LR-1SE; 1R,X; or 10,X); and low risk, zero shared epitopes (LR-0SE; X,X)
(Fries et al. 2002).
d ORs were calculated relative to the major allele homozygote (CC).
e All patients in the discovery cohort are RF.
f Because of the infrequency of the TT genotype, we combined it with the TC genotype for these analyses.
Table 4
Frequency of the PTPN22 Risk Allele in Discovery and






Discovery controls (white) 475 .088
Replication controls (white) 926 .087
Additional whitesa 560 .084
African Americansb 409 .024
Africansc 21 0
Mexican Americansd 99 .035
Han Chinesee 100 0
a Including samples from 360 whites from throughout
the United States (obtained by GCI), 147 North American
whites (obtained from the National Institute of General
Medical Sciences [NIGMS] Human Variation Panels
[HVP]), 10 northern Europeans (NIGMSHVP), 9 Italians
(NIGMS HVP), 8 Greeks (NIGMS HVP), 20 independent
CEPH individuals from Utah (NIGMS), 1 CEPH individ-
ual from France (NIGMS), and 5 Adygei (an indigenous
Circassian people; NIGMS). GCI obtained informedwrit-
ten consent from all participants and local institutional
review board approval at all recruitment sites.
b Including samples from 369 African Americans from
throughout the United States obtained by GCI (see foot-
note a for comments on consent/IRB approval) and 40
African Americans (NIGMS HVP).
c Including samples from 9 sub-Saharan Africans
(NIGMS HVP), 7 northern Africans (north of the Sahara)
(NIGMS HVP), and 5 Pygmies (NIGMS).
d Including samples from 99 Mexican Americans from
Los Angeles (NIGMS HVP).
e Including samples from 100 Han Chinese from Los
Angeles (NIGMS HVP).
ease compared with the CC genotype. Further adjust-
ment for the HLA-DRB1 genotype, the strongest known
genetic risk factor (Seldin et al. 1999), had little impact
on risk estimates. Similar results were observed in the
replication study. The susceptible TT and TC genotypes
were strongly associated with rheumatoid factor–posi-
tive (RF) disease, even after adjustment for the HLA
genotype ( in discovery study, inPp .0197 Pp .0005
replication study) (table 3); however, there was no evi-
dence for association with rheumatoid factor–negative
(RF) disease. This interesting observation has been rep-
licated in an additional cohort of patients with recent-
onset RA (A. T. Lee and P. K. Gregersen, unpublished
data). There was no consistent sex difference in asso-
ciation of the risk allele with RA (data not shown).
To evaluate putative modes of inheritance, we com-
bined the two data sets and used the likelihood-ratio test
(Breslow and Day 1980) on the basis of CLR models.
Although we could exclude a recessive mode of inheri-
tance ( ), the data are consistent with eitherP ! .0001
additive or dominant modes of inheritance. We also gen-
erated estimates of the population-attributable fraction
(0.11 for discovery study [95% CI 0.05–0.17]; 0.16 for
replication study [95% CI 0.10–0.21]) (Schlesselman
1982; Yang et al. 2003). However, these estimates should
be interpreted with caution, since our cases were selected
to have relatively severe disease and thus are not rep-
resentative of the full clinical spectrum of RA.
PTPN22 is located on chromosome 1p13, ∼9 Mb
centromeric to a microsatellite marker, D1S1631, that
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Figure 2 Western blot showing Csk coimmunoprecipitation by
the two HA-tagged PTPN22 proteins (R620 and W620) expressed in
293T cells. W620 decreases the afﬁnity of PTPN22 for Csk. Increasing
the amount of PTPN22 W620 expressed does not increase the amount
of Csk that coimmunoprecipitates. Quantitation of Csk band intensity
indicates a 2.9-fold difference between R620 andW620. Similar results
(2.6-fold) were seen in a second experiment. PTPN22 sequences were
cloned by PCR and veriﬁed to encode a PTPN22 protein sequence
corresponding to Swiss-Prot Q9Y2R2. The R620W variant was in-
troduced (QuikChange [Stratagene]), and both PTPN22 variants with
an N-terminal HA tag were cloned into the pCMV5 expression vector
(Qbiogene). Csk was cloned by PCR, the sequence was veriﬁed, and
it was introduced into the pcDNA-DEST40 expression vector (Invi-
trogen). The 293T (GenHunter) cells ( cells/well) were seeded53# 10
in 12-well plates and were transfected 24 h later by use of 3.5 ml/well
of Lipofectamine 2000 (Invitrogen). Cells were washed and resus-
pended in lysis buffer (50 mM Tris [pH 8.0], 2 mM EDTA, 1% NP-
40, 50 mM NaF, 1 mM sodium orthovanadate, and 1# protease
inhibitor cocktail [Sigma]) 48 h after transfection. HA-PTPN22 im-
munoprecipitations were performed as described elsewhere (Cloutier
and Veillette 1999), with the following modiﬁcations. Before immu-
noprecipatation, detergent-insoluble material was removed by cen-
trifugation ( ) and lysates were pre-cleared by use of mouse100,000# g
IgG agarose beads (Sigma). The lysate (100 mg) was incubated with
15 ml of anti-HA conjugated beads (Sigma) for 2 h at 4C. Beads were
washed three times in wash buffer (50 mM Tris [pH 8.0], 100 mM
NaCl, 2 mM EDTA, 1% NP-40, 50 mM NaF, and 1 mM sodium
orthovanadate). Precipitated proteins and lysates were analyzed by
western blot, by use of anti-HA (Covance) and anti-Csk (Upstate 06-
566) antibodies, and were detected by use of HRP-conjugated sec-
ondary antibodies (Pierce 31430 and Biosource ALI3404) and chemi-
luminescence (Pierce).
shows linkage to RA in the NARAC sib pairs (SIBPAL
) (Jawaheer et al. 2003) from which our rep-Pp .0011
lication study was drawn. Linkage analysis using Allegro
(Gudbjartsson et al. 2000) yielded an insigniﬁcant LOD
score of 0.15 for PTPN22 R620W in these sib pairs,
indicating that R620W is not solely responsible for the
linkage seen at D1S1631. We then conducted stratiﬁed
analyses based on PTPN22 R620W genotypes of the
probands. Among 7, 76, and 193 affected sib pairs for
which the proband had the TT, TC, or CC genotype,
respectively, the respective mean identity-by-descent–
sharing values were 0.598, 0.505, and 0.486, and the
respective nonparametric linkage (NPL) scores were
0.94, 0.35, and 0.46 (Allegro) (Gudbjartsson et al.
2000). These results suggested that R620W has a weak
effect on the 1p13 linkage signal. Li et al. (2004) have
recently shown that there is large variability in NPL
scores when families are stratiﬁed by the genotype of a
single, randomly selected sib, and they developed a pro-
gram (Genotype-IBD Sharing Test [GIST]) in which fam-
ilies are weighted on the basis of the genotypes of all
family members. GIST analysis that was conditional on
the T allele indicated signiﬁcant evidence for linkage
( ). The apparent difference between the sig-P ! .0001
niﬁcance of the stratiﬁed analysis and the GIST results
may reﬂect the increased power of the GIST algorithm,
or, alternatively, the rarity of the TT genotype may lead
to poor convergence of the GIST test statistic to the
asymptotic distribution. Taken together, all these data
suggest that, whereas the SNP may account for a small
part of the linkage signal seen on 1p, it is clearly not
responsible for the entire signal.
We also genotyped this SNP in several additional con-
trol populations (table 4). The observed frequency of the
risk allele in 560 additional white subjects (8.4%) was
consistent with results in our two RA control popula-
tions. When all three control data sets of whites (np
) were combined, the T allele was present in 16.7%1,961
of individuals at an allele frequency of 8.7%. The T allele
frequency was lower in 99 Mexican Americans (3.5%)
and 409 African Americans (2.4%). This allele was not
detected in 100 Han Chinese or 21 Africans. A Fisher’s
Exact Test showed that these differences in allele fre-
quencies were highly signiﬁcant ( ). It will10P ! 1 # 10
be important to expand these studies to determine
whether presence of the T allele in the African American
and Mexican American populations is due to admixture
with whites.
PTPN22 encodes a 110-kD cytoplasmic protein ty-
rosine phosphatase that consists of an N-terminal phos-
phatase domain and a long C-terminal region containing
several proline-rich motifs (Cohen et al. 1999). The
mouse ortholog, PEP (encoded by the murine gene
Ptpn8), has been shown to be a potent down-regulator
of T-cell receptor–dependent responses through its as-
sociation with the SH3 domain of Csk (Cloutier and
Veillette 1999). Although PEP and PTPN22 are only
70% identical at the amino acid level (Cohen et al.
1999), overexpression data suggest PTPN22 may play
a role similar to that of PEP (Hill et al. 2002). To conﬁrm
that PTPN22 functions as a negative regulator of T-cell
activation, we used RNA interference (RNAi) to de-
crease expression in Jurkat cells and then measured the
response to antigen-receptor stimulation. mRNAknock-
down by two independent siRNAs increased T-cell re-
ceptor–dependent activation by approximately two-fold,
as measured by an NF-kB-reporter response (ﬁg. 1). This
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Figure 3 RNA expression proﬁle of PTPN22. Expression of the PTPN22 major splice variant (GenBank accession number NM_015967)
was determined by kinetic RT-PCR analysis by use of total RNA from sorted hematopoeitic cells (AllCells) and selected tissues (Clontech), as
described elsewhere (Rogge et al. 2000). Data for additional tissues are provided online (table A1 [online only]). To eliminate genomic DNA
ampliﬁcation, ampliﬁcation primers (5′-GGTTGAGGAAGCTGGAGAAT and 5′-GGGAGAAGAACGATCTTGATGTA) were selected from dif-
ferent exons. Each RNA sample was also ampliﬁed with seven housekeeping genes, as described elsewhere (Rogge et al. 2000). The level of
expression of these housekeeping genes was used to normalize the amount of message in all samples. The normalized expression levels of
PTPN22 in all normal tissues (excluding tumor cell lines and puriﬁed hematopoietic cells) were averaged, and the results from each individual
sample were expressed as a fold change relative to this average. A positive number indicates more PTPN22 message in the indicated sample
relative to the average of all samples, whereas a negative number means there is less PTPN22 message relative to the overall average.
is consistent with recent results in PEP-deﬁcient mice
(Hasegawa et al. 2004). These animals have rather subtle
phenotypic alterations in T-cell function, with enhanced
activation of Lck and expansion of memory T cells, but
apparently normal naive T-cell function.
The ﬁrst proline-rich domain (P1) of PEP binds the
SH3 domain of the negative regulatory kinase Csk
(Cloutier and Veillette 1996; Gregorieff et al. 1998). Bot-
tini and colleagues (2004) have recently shown that the
R620W SNP (which is located in P1) affects the binding
of PTPN22 to Csk. We conﬁrmed this ﬁnding by co-
transfection of full-length cDNA clones for PTPN22
(R620 or W620) and Csk into 293T cells, followed
by immunoprecipitation of PTPN22. Although both
PTPN22 constructs were expressed at similar levels, 2.5–
3-fold less Csk was coimmunoprecipitated by the W620
protein, relative to the R620 protein (ﬁg. 2). These data
suggest that the association of this missense SNP with
RA may be due to the inability of the variant phospha-
tase to bind Csk and down-regulate T-cell activation.
Prior studies have suggested that PTPN22 is expressed
primarily in hematopoietic tissues (Cohen et al. 1999:
Hill et al. 2002; Chien et al. 2003), such as thymus,
spleen, bone marrow, and peripheral bloodmononuclear
cells (PBMCs). We conﬁrmed and extended these ﬁnd-
ings by examining numerous tissues and speciﬁc PBMC
subsets by use of semiquantitative kinetic RT-PCR (ﬁg.
3 and table A1 [online only]). Expression appeared to
be largely conﬁned to hematopoietic tissues and was
present in all subtypes of normal human PBMCs tested,
including resting CD3 T cells, CD4 T cells, CD8
T cells, B cells, monocytes, neutrophils, dendritic cells,
and natural killer (NK) cells (ﬁg. 3). However, there ap-
pears to be a hierarchy, with NK cells and neutrophils
expressing the most PTPN22 message and B cells and
CD4 T cells expressing the least. These data raise the
possibility that the association of PTPN22 with RA
could also be a result of functional changes in these other
cell types. In particular, monocytosis and monocyte ac-
tivation are characteristic features of RA, and NK and
NK-T cells may also be involved in the pathogenesis of
RA (Kojo et al. 2001; Dalbeth and Callan 2002). As a
consequence, a complete analysis of PTPN22 function
in these cell populations will be required to fully eluci-
date the role of this protein in autoimmunity.
Familial clustering of multiple autoimmune disorders
in the same family is well documented, and ﬁrst-degree
relatives of RA probands have a signiﬁcantly higher
prevalence of type 1 diabetes (T1D [MIM 222100]) than
the general population (Lin et al. 1998). In addition,
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genomewide scans for autoimmune diseases, in both
mouse and human, show colocalization of susceptibility
loci (Becker et al. 1998; Grifﬁths et al. 1999), suggesting
a possible shared genetic basis for autoimmunity. The
ﬁnding that the minor allele of the PTPN22 SNP re-
ported here is also associated with T1D (Bottini et al.
2004) supports the hypothesis that there are common
genetic variants that contribute to general immune dys-
regulation and susceptibility to autoimmunity (Marrack
et al. 2001; Wandstrat and Wakeland 2001). It will be
important to examine PTPN22 associations in a wide
variety of autoimmune diseases and to determine its
functional role in each disease. Although a common un-
derlying mechanism for autoimmunity is tempting to
postulate, given the expression of this molecule in many
immunologically relevant cell types, the possibility re-
mains that PTPN22may act in different ways in different
autoimmune diseases.
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